Doctors test gene therapy to protect brain cells in Parkinson's patients
NCT ID NCT04167540
Summary
This early-stage study is testing the safety of a one-time gene therapy for Parkinson's disease. The therapy aims to deliver a protective protein (GDNF) directly into a specific brain region to support the cells affected by the disease. The study involves 11 participants with Parkinson's and will monitor them for side effects and any changes in their symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Ohio State University Medical Center
Columbus, Ohio, 43210, United States
-
University of California Irvine
Irvine, California, 92697, United States
-
University of California San Francisco
San Francisco, California, 94103, United States
Conditions
Explore the condition pages connected to this study.